ClinicalTrials.gg
RecruitingNCT07240220Merck-4Updated Nov 10, 2026

The Mother-Daughter Project: Merck-4

An interventional study of Gardasil-9 and High Risk HPV DNA Testing in Cervical Dysplasia, sponsored by Indiana University. Recruiting at 1 site in Kenya. Open to female participants aged 9 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Indiana University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,500
Allocation
Non-randomized
Ages
9 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Uterine Cervical Dysplasia with a site in Kenya — 4 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Dysplasia · Kenya.

Planned enrollment
2nd of 10
2,500 · median 350
Started
2026
with 3 others
No phase
6 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
2 of 11
Indiana University

Among the 11 studies in Uterine Cervical Dysplasia with a site in Kenya, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, and was the 8th registered.

Uterine Cervical Dysplasia

410 studies on the registry are indexed under Uterine Cervical Dysplasia; 77 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

4 of the 11 studies in Uterine Cervical Dysplasia with a site in Kenya are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Kenya have not opened yet or have stopped. Only those recruiting at a site in Kenya →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 9 Years to 49 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Uterine Cervical Dysplasia with a site in Kenya, or all of them as a file.
02

Study summary

This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children.

This project specifically aims to collect additional data on the ability for HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women, to investigate and identify barriers leading to non-participation in previous MDP efforts, and to examine factors associated with the immune response to HPV vaccination among rural Kenyan girls.

Read the detailed description

Cervical cancer is caused by oncogenic, or "high-risk" (HR) human papillomavirus (HPV) and is the main cause of cancer-related death among Kenyan women. Although preventable, this malignancy occurs frequently in women living in rural areas of Kenya where screening is seldom performed, and girls are not vaccinated against HPV. Only 5% of Kenyan women are regularly screened, and 14% have ever been screened, done in Kenya by a method known as Visual Inspection with Acetic Acid (VIA). Obstacles to effective screening include long travel to clinics, high costs, and factors related to VIA such as poor sensitivity and specificity, the need for practitioner training for VIA, variability among providers in VIA interpretation, and others. In addition, while safe and effective HPV vaccines have been available since 2006, very few (\<5%) Kenyan girls have been vaccinated. Obstacles to vaccination include high costs, poor delivery infrastructure, lack of education, long travel to clinics, and others. Additionally, strategies based on centralized care have been unsuccessful in preventing cervical cancer in Kenyan women.

In 2018, an initiative known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), was developed in the Webuye region of Western Kenya. Early work from the MDP demonstrated that self-collection of cervical swabs, and the administration of HPV vaccination, is acceptable and feasible within a community rural setting. This continuation project will further study the utility of this strategy, elucidate the barriers to participation, and begin to provide information about the impact of the program.

An additional cohort of 500 adult women will be enrolled in the cervical cancer screening initiative to strengthen the power of analysis on HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women (Aim 1). Second, families who were invited to the MDP but declined to participate will be identified to investigate and identify barriers leading to their non-participation of the MDP (Aim 2). Third, vaccination efforts will be expanded through the enrollment of an additional 2000 girls, and factors associated with the immune response to HPV vaccination among 9- to 14-year-old rural Kenyan girls will be examined (Aim 3).

This prospective cohort study will be conducted in Webuye, a community located in the western region of Kenya, in Bungoma County on the highway to Uganda. A "Community Entry Strategy" was utilized to introduce prior studies and to invite women to community meetings. A female Kenyan Counselor was trained about cervical cancer (including the cause and the ways to prevent the cancer), how to educate women about this malignancy and how to instruct women in performance of self-collected swabs. Village chiefs, village elders, women deemed to be community leaders, and leaders of the local churches have been approached by the Counselor and Study Coordinator to discuss the goals, strategy, and risks and benefits of the study; this process will be repeated before the current study is initiated. Discussions have focused on the importance of early screening for cervical cancer, the use of self-collected swabs for screening, and the importance of vaccination of children against HPV.

For Aim 1, an additional 500 Kenyan women between the ages of 25 to 49 years (the government-recommended age range for screening in Kenya) will be enrolled. Only women who did not participate in our MDP studies will be enrolled. Women will be instructed in collecting vaginal swabs during the community meetings, and these self-collected swabs will be given to the Counselor. Swabs will be tested for HR-HPV DNA at Lancet Laboratories in Nairobi (or at Moi University if reagents can be obtained) using the Roche Cobas Assay. All women will be asked to travel to the Webuye Clinic for pelvic examination and VIA (the Kenyan standard of care). Cervical biopsy will be performed on all HIV-infected women and on those HIV-uninfected women with abnormal VIA examinations. Results will be analyzed to determine the sensitivity, specificity, positive predictive value, and negative predictive value for HR-HPV DNA to predict biopsy-proven cervical intraepithelial lesion grades 2 and 3, or invasive cancer (CIN2/3) in the HIV-infected group of women.

For Aim 2, adult women and their daughters (if they have daughters), will be asked to fill out questionnaires that will provide data about educational aspects and overall acceptability of the MDP and obstacles related to its initiation. This will be done following the second vaccine dose that will be administered to girls at community meetings. Women in the Webuye community have been satisfied with self-collection of swabs as a method of cervical cancer screening, and most are willing to have their daughters vaccination against HPV. However, it is important to identify those women who do not want to attend meetings, do not want to provide self-collected swabs, or do not want their daughters vaccinated against HPV infection. These women will be traced through 1) records that will be acquired for all women who attend the community meeting, 2) records about women who refuse to participate, and 3) meeting in person (home visits) with women who decline through their phone contacts, through community leaders who understand their physical locations.

For Aim 3, an additional 2000 girls, ages 9 through 14, will be enrolled and the first 9v HPV vaccine will be administered to these girls at a community meeting. The second dose of the HPV vaccine will be administered six to twelve months after the first dose at a subsequent community meeting. Factors associated with the immunological response to the 9v HPV vaccine will additionally be studied. For that purpose, 120 girls will have a blood sample taken at a community meeting, approximately 24 months after receiving the second 9v HPV vaccine dose. Each girl's BMI will be determined. The blood sample will be analyzed for plasma aflatoxin, antibody titers to each of the nine HPV types represented in the 9v vaccine, and for folate, iron, and hemoglobin. In addition, girls will be interviewed with their mothers regarding specific dietary habits.

03

Conditions studied

  • Cervical Dysplasia

Keywords

  • cervical dysplasia
  • cervical cancer screening
  • HPV infection
04

Who can participate

Ages eligible
9 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Kenyan Adult Women

Inclusion Criteria:

  • ages 25 through 49 years
  • able/willing to sign
  • willing to participate in the community meetings

Exclusion Criteria:

  • pregnant

Kenyan Girls

Inclusion Criteria:

  • ages 9 through 14 years
  • have mother that is able/willing to sign informed consent for vaccination
  • can return for the second HPV vaccine dose in 6 - 12 months

Exclusion Criteria:

  • girls who are not willing or unable to return for the second HPV vaccine dose
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Other
    Kenyan women

    Up to 500 adult women will undergo cervical cancer screening.

    Diagnostic Test: High Risk HPV DNA Testing · Procedure: Visual Inspection with acetic acid (VIA) and possible cervical biopsy

  • Other
    Kenyan daughters

    Up to an additional 2000 girls (daughters of participants in the Kenyan women arm) will be immunized against HPV using the 9-valent HPV vaccine (Gardasil-9).

    Biological: Gardasil-9

Interventions

  • BiologicalHuman Papillomavirus Recombinant Vaccine nonavalentStudies of Human Papillomavirus Recombinant Vaccine nonavalentHuman Papillomavirus Recombinant Vaccine nonavalent pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The 9 valent vaccine will be offfered to 2000 adolescent girls. The 9 valent vaccine will be offered to 2000 adolescent girls. The first vaccination dose will be administered at a community meeting, after parental consent has been obtained. The second vaccination dose will be administered at a subsequent community meeting, 6 to 12 months after the first dose.

    Also known as: 9-valent HPV vaccine

  • Diagnostic testHigh Risk HPV DNA Testing

    Self-collected cervical swabs will be tested for high-risk HPV using the Roche Cobas Assay. This assay provides specific HPV 16 or 18 detection, as well as detection of any of 12 additional oncogenic types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).

  • ProcedureVisual Inspection with acetic acid (VIA) and possible cervical biopsy

    Cervical screening in Kenya is usually done through pelvic examination and VIA. Cervical biopsy will additionally be performed for all HIV-infected women, and for HIV-uninfected women with abnormal VIA results.

06

What researchers measure

Primary outcomes

  1. Detection of CIN2/3

    Following a community meeting at which education on cervical cancer, self-collection of swabs for analysis and HPV vaccination are discussed, participating adult women will provide a self collected swab that will be analyzed for high risk HPV. All participating adult women will additionally undergo pelvic examination and VIA (the Kenyan standard of care). Cervical biopsy will be performed on all HIV-infected women and those HIV-uninfected women with abnormal VIA examinations. For the cohort of women who will undergo cervical biopsy, the rates of HR-HPV positivity, VIA abnormality and CIN2/3 detection will be reported for all women and by HIV status. Sensitivity, specificity, positive predictive value, and negative predictive value between HR-HPV and VIA in the detection of biopsy-proven cervical intraepithelial lesion grades 2 and 3, or invasive cancer (CIN2/3) will be compared.

    Time frame: Baseline

  2. Local knowledge and attitudes

    Adult women and their daughters (if they have daughters), will be asked to fill out questionnaires that will evaluate women's knowledge of cervical cancer screening and HPV vaccination and attitudes towards their own health and health of their daughters.

    Time frame: Baseline and after HPV vaccination of daughters is complete (assessed 2 weeks after second vaccine)

  3. Barriers to participation

    Both women who attend the MDP community meeting but decline to participate, and women in the village who were invited but did not attend the community meeting can be identified by the local counselor. The counselor will later contact these women for an interview to determine the reasons for declining participation. It is expected that 20 non-participants will be interviewed to identify barriers. Specific barriers mentioned by the women will then be grouped into several categories. Potential categories may be "lack of confidence in safety of the procedures" (self-collection swab or HPV vaccination of children), "other obligations competing for time", or "cultural-related inhibition". The frequency and percentage of each specific barrier mentioned by the women will be reported.

    Time frame: During a one-time interview

  4. Factors that influence immunity to the HPV vaccine

    The HPV vaccine will be administered at community meetings to participating girls. Approximately 24 months after receiving the second vaccine dose, a subset of girls will undergo a blood sample and BMI measurement at another community meeting. The blood sample will be analyzed for plasma aflatoxin, for antibody titers to each of the nine HPV types in the vaccine, and for folate, iron, and hemoglobin (indicators of nutrition). The girls will also be interviewed with their mothers regarding specific dietary habits.

    Time frame: 24 months after second HPV vaccine

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

Of 78 non-industry interventional studies with no phase under Uterine Cervical Dysplasia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 24 months is close to that.

Counting every sponsor, half of 82 studies reached it within 26 months; a quarter within 13 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jul 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Jul 22, 2026was Feb 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Moi University is now Recruiting
Nov 10, 2026
Start date
Feb 1, 2026→Jul 22, 2026 (actual)
Nov 10, 2026
Interventions
Changed Gardisil-9→Gardasil-9
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Moi University · Eldoret, KenyaContact d•••@iu.edu · •••9034→a•••@iu.edu · •••8271
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Moi University is now Recruiting
    Start date Feb 1, 2026→Jul 22, 2026 (now actual)
    Interventions Changed Gardisil-9→Gardasil-9
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Moi University · Eldoret, KenyaContact d•••@iu.edu · •••9034→a•••@iu.edu · •••8271
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07240220
Lead sponsor
Indiana University
Responsible party
Aaron C. Ermel, MD (Professor of Microbiology, Indiana University) — Principal investigator
First posted
Nov 20, 2025
Start date
Jul 22, 2026
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Phillip Tonui, MD
Contact
tonui46@yahoo.co.uk
0722 609132

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion